1. Home
  2. VIR vs CII Comparison

VIR vs CII Comparison

Compare VIR & CII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$7.61

Market Cap

843.1M

Sector

Health Care

ML Signal

HOLD

Logo Blackrock Capital and Income Fund Inc.

CII

Blackrock Capital and Income Fund Inc.

HOLD

Current Price

$23.09

Market Cap

963.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIR
CII
Founded
2016
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
843.1M
963.2M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
VIR
CII
Price
$7.61
$23.09
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$28.63
N/A
AVG Volume (30 Days)
1.7M
78.8K
Earning Date
02-25-2026
01-01-0001
Dividend Yield
N/A
6.17%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$16,860,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.16
$16.76
52 Week High
$11.39
$19.81

Technical Indicators

Market Signals
Indicator
VIR
CII
Relative Strength Index (RSI) 67.87 42.58
Support Level $5.80 $22.99
Resistance Level $6.90 $23.40
Average True Range (ATR) 0.47 0.24
MACD 0.16 -0.02
Stochastic Oscillator 92.50 11.33

Price Performance

Historical Comparison
VIR
CII

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

About CII Blackrock Capital and Income Fund Inc.

Blackrock Enhanced Cap&Inc Fund, Inc is a closed-end management investment company. Its objective is to provide total return through a combination of current income and capital appreciation. The trust seeks to achieve its investment objective by investing a majority of its total assets in a portfolio of equity securities of U.S. and foreign issuers.

Share on Social Networks: